{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:06:57Z","timestamp":1787771217362,"version":"build-2784847793"},"reference-count":64,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Perinatology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1053\/j.semperi.2017.08.004","type":"journal-article","created":{"date-parts":[[2017,9,23]],"date-time":"2017-09-23T04:45:18Z","timestamp":1506141918000},"page":"461-467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?"],"prefix":"10.1053","volume":"41","author":[{"given":"Tracy A.","family":"Manuck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.semperi.2017.08.004_bib1","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2006-2386","article-title":"Cost of hospitalization for preterm and low birth weight infants in the United States","volume":"120","author":"Russell","year":"2007","journal-title":"Pediatrics"},{"issue":"1","key":"10.1053\/j.semperi.2017.08.004_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ajog.2016.01.004","article-title":"Preterm neonatal morbidity and mortality by gestational age: a contemporary cohort","volume":"215","author":"Manuck","year":"2016","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"10.1053\/j.semperi.2017.08.004_bib3","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ajog.2014.01.046","article-title":"Correlation between initial neonatal and early childhood outcomes following preterm birth","volume":"210","author":"Manuck","year":"2014","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1053\/j.semperi.2017.08.004_bib4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1055\/s-0035-1571150","article-title":"Short- and long-term outcomes of moderate and late preterm infants","volume":"33","author":"Natarajan","year":"2016","journal-title":"Am J Perinatol"},{"issue":"5","key":"10.1053\/j.semperi.2017.08.004_bib5","doi-asserted-by":"crossref","first-page":"e1014","DOI":"10.1542\/peds.2007-2976","article-title":"Impact of intensive care practices on short-term and long-term outcomes for extremely preterm infants: comparison between the British Isles and France","volume":"122","author":"Bodeau-Livinec","year":"2008","journal-title":"Pediatrics"},{"issue":"4","key":"10.1053\/j.semperi.2017.08.004_bib6","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.clp.2013.07.006","article-title":"Long-term outcomes of moderately preterm, late preterm, and early term infants","volume":"40","author":"Vohr","year":"2013","journal-title":"Clin Perinatol"},{"issue":"6","key":"10.1053\/j.semperi.2017.08.004_bib7","doi-asserted-by":"crossref","first-page":"e17965","DOI":"10.5812\/ircmj.17965","article-title":"Long-term neurodevelopmental outcomes after preterm birth","volume":"16","author":"Soleimani","year":"2014","journal-title":"Iran Red Crescent Med J"},{"issue":"6","key":"10.1053\/j.semperi.2017.08.004_bib8","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1542\/peds.2005-0171","article-title":"Neurodevelopmental outcome at 5 years of age of a national cohort of extremely low birth weight infants who were born in 1996\u20131997","volume":"116","author":"Mikkola","year":"2005","journal-title":"Pediatrics"},{"issue":"6","key":"10.1053\/j.semperi.2017.08.004_bib9","doi-asserted-by":"crossref","first-page":"e725","DOI":"10.1542\/peds.2004-0932","article-title":"Psychosocial and academic characteristics of extremely low birth weight (< or =800 g) adolescents who are free of major impairment compared with term-born control subjects","volume":"114","author":"Grunau","year":"2004","journal-title":"Pediatrics"},{"issue":"suppl 2","key":"10.1053\/j.semperi.2017.08.004_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/14767050902860690","article-title":"The preterm parturition syndrome and its implications for understanding the biology, risk assessment, diagnosis, treatment and prevention of preterm birth","volume":"22","author":"Gotsch","year":"2009","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"2","key":"10.1053\/j.semperi.2017.08.004_bib11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ajog.2011.10.864","article-title":"Challenges in defining and classifying the preterm birth syndrome","volume":"206","author":"Kramer","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1053\/j.semperi.2017.08.004_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1471-0528.1990.tb01740.x","article-title":"Progestogen administration in pregnancy may prevent preterm delivery","volume":"97","author":"Keirse","year":"1990","journal-title":"Br J Obstet Gynaecol"},{"issue":"24","key":"10.1053\/j.semperi.2017.08.004_bib13","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa035140","article-title":"Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate","volume":"348","author":"Meis","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.semperi.2017.08.004_bib14","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/uog.6418","article-title":"Effect of mifepristone on the corpus luteum in early pregnancy","volume":"34","author":"Niinimaki","year":"2009","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"12","key":"10.1053\/j.semperi.2017.08.004_bib15","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/14767050600949829","article-title":"Mechanisms of progesterone action in inhibiting prematurity","volume":"19","author":"Sfakianaki","year":"2006","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"7","key":"10.1053\/j.semperi.2017.08.004_bib16","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1210\/me.2009-0016","article-title":"Minireview: fetal-maternal hormonal signaling in pregnancy and labor","volume":"23","author":"Mendelson","year":"2009","journal-title":"Mol Endocrinol"},{"issue":"1","key":"10.1053\/j.semperi.2017.08.004_bib17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0950-351X(87)80059-9","article-title":"The antiprogesterone steroid RU 486: a short pharmacological and clinical review, with emphasis on the interruption of pregnancy","volume":"1","author":"Garfield","year":"1987","journal-title":"Baillieres Clin Endocrinol Metab"},{"issue":"3","key":"10.1053\/j.semperi.2017.08.004_bib18","first-page":"125","article-title":"Progesterone receptor localization and isoforms in myometrium, decidua, and fetal membranes from rhesus macaques: evidence for functional progesterone withdrawal at parturition","volume":"9","author":"Haluska","year":"2002","journal-title":"J Soc Gynecol Investig"},{"issue":"3 Pt 2","key":"10.1053\/j.semperi.2017.08.004_bib19","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.ajog.2005.05.071","article-title":"Progesterone receptor isoform (A\/B) ratio of human fetal membranes increases during term parturition","volume":"193","author":"Oh","year":"2005","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1053\/j.semperi.2017.08.004_bib20","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.4049\/jimmunol.181.2.1470","article-title":"Monocyte chemoattractant protein-1 (CCL-2) integrates mechanical and endocrine signals that mediate term and preterm labor","volume":"181","author":"Shynlova","year":"2008","journal-title":"J Immunol"},{"issue":"2","key":"10.1053\/j.semperi.2017.08.004_bib21","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ajog.2005.08.057","article-title":"Human spontaneous labor without histologic chorioamnionitis is characterized by an acute inflammation gene expression signature","volume":"195","author":"Haddad","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"10.1053\/j.semperi.2017.08.004_bib22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12958-015-0111-3","article-title":"In vitro progesterone modulation on bacterial endotoxin-induced production of IL-1beta, TNFalpha, IL-6, IL-8, IL-10, MIP-1 alpha, and MMP-9 in pre-labor human term placenta","volume":"13","author":"Garcia-Ruiz","year":"2015","journal-title":"Reprod Biol Endocrinol"},{"issue":"6","key":"10.1053\/j.semperi.2017.08.004_bib23","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ajog.2015.08.010","article-title":"Vaginal progesterone, but not 17alpha-hydroxyprogesterone caproate, has antiinflammatory effects at the murine maternal-fetal interface","volume":"213","author":"Furcron","year":"2015","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1053\/j.semperi.2017.08.004_bib24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ajog.2013.01.020","article-title":"Prevention of preterm birth by progestational agents: what are the molecular mechanisms?","volume":"208","author":"Nold","year":"2013","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1053\/j.semperi.2017.08.004_bib25","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.ajog.2006.06.013","article-title":"The use of progestational agents for preterm birth: lessons from a mouse model","volume":"195","author":"Elovitz","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"10.1053\/j.semperi.2017.08.004_bib26","series-title":"Analytic Profiles of Drug Substances","doi-asserted-by":"crossref","DOI":"10.1016\/S0099-5428(08)60014-3","article-title":"Hydroxyprogesterone caproate","author":"Florey","year":"1975"},{"issue":"13","key":"10.1053\/j.semperi.2017.08.004_bib27","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.2146\/ajhp130466","article-title":"Stability of hydroxyprogesterone caproate alone and in a compounded pharmaceutical product","volume":"71","author":"Zhao","year":"2014","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"10.1053\/j.semperi.2017.08.004_bib28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ajog.2011.03.028","article-title":"Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation","volume":"205","author":"Caritis","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"10.1053\/j.semperi.2017.08.004_bib29","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ajog.2012.08.015","article-title":"Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation","volume":"207","author":"Caritis","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"8","key":"10.1053\/j.semperi.2017.08.004_bib30","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1124\/dmd.115.064998","article-title":"Variability in expression of CYP3A5 in human fetal liver","volume":"43","author":"Vyhlidal","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1053\/j.semperi.2017.08.004_bib31","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/bcp.12990","article-title":"Population pharmacokinetics of 17alpha-hydroxyprogesterone caproate in singleton gestation","volume":"82","author":"Sharma","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1053\/j.semperi.2017.08.004_bib32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"issue":"2","key":"10.1053\/j.semperi.2017.08.004_bib33","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ajog.2013.10.008","article-title":"Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth","volume":"210","author":"Caritis","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"10.1053\/j.semperi.2017.08.004_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2017.02.025","article-title":"17-alpha hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study","author":"Nelson","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1053\/j.semperi.2017.08.004_bib35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ajog.2010.02.004","article-title":"Care for women with prior preterm birth","volume":"203","author":"Iams","year":"2010","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1053\/j.semperi.2017.08.004_bib36","first-page":"444","article-title":"Pregnancy outcome following a second-trimester loss","volume":"81","author":"Goldenberg","year":"1993","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1053\/j.semperi.2017.08.004_bib37","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/AOG.0b013e3182723b1b","article-title":"Practice bulletin no. 130: prediction and prevention of preterm birth","volume":"120","year":"2012","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1053\/j.semperi.2017.08.004_bib38","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ajog.2012.03.010","article-title":"Progesterone and preterm birth prevention: translating clinical trials data into clinical practice","volume":"206","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1053\/j.semperi.2017.08.004_bib39","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/AOG.0000000000000048","article-title":"Preterm birth rates in a prematurity prevention clinic after adoption of progestin prophylaxis","volume":"123","author":"Markham","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1053\/j.semperi.2017.08.004_bib40","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/01.AOG.0000281348.51499.bc","article-title":"Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo","volume":"110","author":"Northen","year":"2007","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1053\/j.semperi.2017.08.004_bib41","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S1043-2760(03)00003-1","article-title":"Progesterone in gestational diabetes mellitus: guilty or not guilty?","volume":"14","author":"Branisteanu","year":"2003","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"10.1053\/j.semperi.2017.08.004_bib42","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ajog.2009.06.036","article-title":"The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies","volume":"201","author":"Gyamfi","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"10.1053\/j.semperi.2017.08.004_bib43","doi-asserted-by":"crossref","first-page":"563243","DOI":"10.1155\/2014\/563243","article-title":"Maternal characteristics influencing the development of gestational diabetes in obese women receiving 17-alpha-hydroxyprogesterone caproate","volume":"2014","author":"Egerman","year":"2014","journal-title":"J Obes"},{"issue":"3","key":"10.1053\/j.semperi.2017.08.004_bib44","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ajog.2011.06.043","article-title":"Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery","volume":"205","author":"Gonzalez-Quintero","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"10.1053\/j.semperi.2017.08.004_bib45","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3109\/14767058.2011.614657","article-title":"Recurrent preterm birth in women treated with 17 alpha-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy","volume":"25","author":"Coleman","year":"2012","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"5","key":"10.1053\/j.semperi.2017.08.004_bib46","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ajog.2016.07.013","article-title":"Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system","volume":"215","author":"Manuck","year":"2016","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1053\/j.semperi.2017.08.004_bib47","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ajog.2015.12.010","article-title":"Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth","volume":"214","author":"Manuck","year":"2016","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1053\/j.semperi.2017.08.004_bib48","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/1471-0528.13744","article-title":"Pharmacogenomics of preterm birth prevention and treatment","volume":"123","author":"Manuck","year":"2016","journal-title":"BJOG"},{"issue":"4","key":"10.1053\/j.semperi.2017.08.004_bib49","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ajog.2014.01.013","article-title":"Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention","volume":"210","author":"Manuck","year":"2014","journal-title":"Am J Obstet Gynecol"},{"issue":"8","key":"10.1053\/j.semperi.2017.08.004_bib50","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1055\/s-0032-1311979","article-title":"Pregnancy outcomes of women receiving compounded 17 alpha-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011","volume":"29","author":"Sibai","year":"2012","journal-title":"Am J Perinatol"},{"issue":"2","key":"10.1053\/j.semperi.2017.08.004_bib51","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ajog.2014.12.011","article-title":"Why the United States preterm birth rate is declining","volume":"213","author":"Schoen","year":"2015","journal-title":"Am J Obstet Gynecol"},{"issue":"9862","key":"10.1053\/j.semperi.2017.08.004_bib52","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0140-6736(12)61856-X","article-title":"Preventing preterm births: analysis of trends and potential reductions with interventions in 39 countries with very high human development index","volume":"381","author":"Chang","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"10.1053\/j.semperi.2017.08.004_bib53","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1055\/s-0029-1215432","article-title":"Attitudes and practices regarding use of progesterone to prevent preterm births","volume":"26","author":"Henderson","year":"2009","journal-title":"Am J Perinatol"},{"issue":"1","key":"10.1053\/j.semperi.2017.08.004_bib54","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/1471-0528.13061","article-title":"Prevention of preterm delivery with vaginal progesterone in women with preterm labour (4P): randomised double-blind placebo-controlled trial","volume":"122","author":"Martinez de Tejada","year":"2015","journal-title":"BJOG"},{"issue":"4","key":"10.1053\/j.semperi.2017.08.004_bib55","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ajog.2015.03.031","article-title":"Vaginal progesterone for maintenance tocolysis: a systematic review and metaanalysis of randomized trials","volume":"213","author":"Suhag","year":"2015","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1053\/j.semperi.2017.08.004_bib56","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ajog.2015.01.054","article-title":"17-alpha-hydroxyprogesterone caproate for maintenance tocolysis: a systematic review and metaanalysis of randomized trials","volume":"213","author":"Saccone","year":"2015","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"10.1053\/j.semperi.2017.08.004_bib57","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa070641","article-title":"A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins","volume":"357","author":"Rouse","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.semperi.2017.08.004_bib58","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ajog.2013.01.032","article-title":"Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial","volume":"208","author":"Senat","year":"2013","journal-title":"Am J Obstet Gynecol"},{"issue":"2 Pt 1","key":"10.1053\/j.semperi.2017.08.004_bib59","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/AOG.0b013e318193c677","article-title":"Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial","volume":"113","author":"Caritis","year":"2009","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1053\/j.semperi.2017.08.004_bib60","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ajog.2012.09.013","article-title":"17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30mm","volume":"207","author":"Grobman","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1053\/j.semperi.2017.08.004_bib61","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ajog.2014.10.1097","article-title":"17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial","volume":"212","author":"Winer","year":"2015","journal-title":"Am J Obstet Gynecol"},{"issue":"3 Pt 2","key":"10.1053\/j.semperi.2017.08.004_bib62","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.ajog.2005.05.077","article-title":"Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery","volume":"193","author":"Spong","year":"2005","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1053\/j.semperi.2017.08.004_bib63","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ajog.2015.08.014","article-title":"Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women?","volume":"213","author":"Heyborne","year":"2015","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1053\/j.semperi.2017.08.004_bib64","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ajog.2015.04.018","article-title":"Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate","volume":"213","author":"Co","year":"2015","journal-title":"Am J Obstet Gynecol"}],"container-title":["Seminars in Perinatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146000517300927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146000517300927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T08:47:34Z","timestamp":1635583654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146000517300927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":64,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0146000517300927"],"URL":"https:\/\/doi.org\/10.1053\/j.semperi.2017.08.004","relation":{},"ISSN":["0146-0005"],"issn-type":[{"value":"0146-0005","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Perinatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semperi.2017.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}